Teva Pharmaceutical/$TEVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Teva Pharmaceutical
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ticker
$TEVA
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Tel Aviv, Israel
Employees
37,000
Website
TEVA Metrics
BasicAdvanced
$19B
-
-$1.14
0.61
-
Price and volume
Market cap
$19B
Beta
0.61
52-week high
$22.80
52-week low
$12.47
Average daily volume
11M
Financial strength
Current ratio
1.033
Quick ratio
0.455
Long term debt to equity
263.487
Total debt to equity
270.203
Interest coverage (TTM)
3.52%
Profitability
EBITDA (TTM)
4,481
Gross margin (TTM)
49.16%
Net profit margin (TTM)
-7.74%
Operating margin (TTM)
20.76%
Effective tax rate (TTM)
-154.83%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.31%
Return on equity (TTM)
-19.11%
Valuation
Price to revenue (TTM)
1.132
Price to book
3.04
Price to tangible book (TTM)
-1.42
Price to free cash flow (TTM)
24.594
Free cash flow yield (TTM)
4.07%
Free cash flow per share (TTM)
67.42%
Growth
Revenue change (TTM)
3.82%
Earnings per share change (TTM)
167.96%
3-year revenue growth (CAGR)
2.22%
10-year revenue growth (CAGR)
-1.96%
3-year earnings per share growth (CAGR)
27.06%
10-year earnings per share growth (CAGR)
-9.81%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Bulls say / Bears say
Teva's cost-cutting initiatives, including a $700 million program, are expected to improve operating margins and fund pipeline programs, with JPMorgan upgrading the stock to 'overweight' and raising the price target to $23. (finviz.com)
The company's specialty drug Austedo reported a 39% increase in worldwide revenue, reaching $411 million in Q1 2025, indicating strong growth in high-margin products. (finviz.com)
Teva's divestiture of its active pharmaceutical ingredient business is seen as a strategic move to focus on core operations, leading to a 2.7% premarket stock rise upon announcement. (tradingview.com)
Teva's Q4 2024 adjusted earnings declined by 29% year-over-year, with revenues falling 5%, partly due to the absence of a $500 million upfront payment received in the prior-year quarter. (nasdaq.com)
The company faced a legal setback when the U.S. Court of Appeals upheld Johnson & Johnson's patent on Invega Sustenna, preventing Teva from producing a generic version and limiting potential revenue streams. (reuters.com)
Teva's stock declined by 13.5% following the release of Q4 earnings, reflecting investor concerns over the company's financial performance and future outlook. (fool.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
TEVA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Teva Pharmaceutical stock?
Teva Pharmaceutical (TEVA) has a market cap of $19B as of July 25, 2025.
What is the P/E ratio for Teva Pharmaceutical stock?
The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of July 25, 2025.
Does Teva Pharmaceutical stock pay dividends?
No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Teva Pharmaceutical dividend payment date?
Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Teva Pharmaceutical?
Teva Pharmaceutical (TEVA) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.